Update on cellular transplantation into the CNS as a novel therapy for chronic pain

Kimberly A. Czech, Jacqueline Sagen

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The transplantation of cells that secrete neuroactive substances with analgesic properties into the CNS is a novel method that challenges current approaches in treating chronic pain. This review covers pre-clinical and clinical studies from both allogeneic and xenogeneic sources. One cell source that has been utilized successfully is the adrenal chromaffin cell, since such cells constitutively release catecholamines, opioid peptides, and neurotrophic factors; release can be augmented with nicotine. Other graft sources include AtT-20 and B-16 cell lines which release enkephalins and catecholamines, respectively. For grafting in rodents, adrenal medullary tissue pieces are transplanted to the subarachnoid space. Chromaffin cell transplants can decrease pain sensitivity in normal rats using standard acute pain tests (paw-pinch, hot-plate, and tail-flick). In addition, transplants can restore normal pain thresholds in rodent models of chronic pain (formalin, adjuvant-induced arthritis, and sciatic-nerve tie) which closely similate the pathologies of human chronic pairs conditions. Xenografts have been studied due to concerns that future application for human pain may be limited by donor availability. Despite immune privileges of the CNS, xenografts require at least short-term immunosuppression to obtain a viable graft. Cell encapsulation is one method of sustaining a xenograft (in rat and human hosts) while circumventing the need for immunosuppression.Clinical studies have been initiated for terminal cancer patients with promising results as assessed by markedly reduced narcotic intake, visual analog scale ratings, and increased CSF levels of catecholamines and met-enkephalin.

Original languageEnglish
Pages (from-to)507-529
Number of pages23
JournalProgress in Neurobiology
Volume46
Issue number5
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Chronic Pain
Transplantation
Heterografts
Catecholamines
Transplants
Chromaffin Cells
Immunosuppression
Rodentia
Pain
Methionine Enkephalin
Subarachnoid Space
Pain Threshold
Experimental Arthritis
Opioid Peptides
Enkephalins
Narcotics
Cell Transplantation
Nerve Growth Factors
Acute Pain
Sciatic Nerve

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Update on cellular transplantation into the CNS as a novel therapy for chronic pain. / Czech, Kimberly A.; Sagen, Jacqueline.

In: Progress in Neurobiology, Vol. 46, No. 5, 01.01.1995, p. 507-529.

Research output: Contribution to journalArticle

@article{e9a5c911bb0e46aa911106c52f7c04a8,
title = "Update on cellular transplantation into the CNS as a novel therapy for chronic pain",
abstract = "The transplantation of cells that secrete neuroactive substances with analgesic properties into the CNS is a novel method that challenges current approaches in treating chronic pain. This review covers pre-clinical and clinical studies from both allogeneic and xenogeneic sources. One cell source that has been utilized successfully is the adrenal chromaffin cell, since such cells constitutively release catecholamines, opioid peptides, and neurotrophic factors; release can be augmented with nicotine. Other graft sources include AtT-20 and B-16 cell lines which release enkephalins and catecholamines, respectively. For grafting in rodents, adrenal medullary tissue pieces are transplanted to the subarachnoid space. Chromaffin cell transplants can decrease pain sensitivity in normal rats using standard acute pain tests (paw-pinch, hot-plate, and tail-flick). In addition, transplants can restore normal pain thresholds in rodent models of chronic pain (formalin, adjuvant-induced arthritis, and sciatic-nerve tie) which closely similate the pathologies of human chronic pairs conditions. Xenografts have been studied due to concerns that future application for human pain may be limited by donor availability. Despite immune privileges of the CNS, xenografts require at least short-term immunosuppression to obtain a viable graft. Cell encapsulation is one method of sustaining a xenograft (in rat and human hosts) while circumventing the need for immunosuppression.Clinical studies have been initiated for terminal cancer patients with promising results as assessed by markedly reduced narcotic intake, visual analog scale ratings, and increased CSF levels of catecholamines and met-enkephalin.",
author = "Czech, {Kimberly A.} and Jacqueline Sagen",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0301-0082(95)00011-J",
language = "English",
volume = "46",
pages = "507--529",
journal = "Progress in Neurobiology",
issn = "0301-0082",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Update on cellular transplantation into the CNS as a novel therapy for chronic pain

AU - Czech, Kimberly A.

AU - Sagen, Jacqueline

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The transplantation of cells that secrete neuroactive substances with analgesic properties into the CNS is a novel method that challenges current approaches in treating chronic pain. This review covers pre-clinical and clinical studies from both allogeneic and xenogeneic sources. One cell source that has been utilized successfully is the adrenal chromaffin cell, since such cells constitutively release catecholamines, opioid peptides, and neurotrophic factors; release can be augmented with nicotine. Other graft sources include AtT-20 and B-16 cell lines which release enkephalins and catecholamines, respectively. For grafting in rodents, adrenal medullary tissue pieces are transplanted to the subarachnoid space. Chromaffin cell transplants can decrease pain sensitivity in normal rats using standard acute pain tests (paw-pinch, hot-plate, and tail-flick). In addition, transplants can restore normal pain thresholds in rodent models of chronic pain (formalin, adjuvant-induced arthritis, and sciatic-nerve tie) which closely similate the pathologies of human chronic pairs conditions. Xenografts have been studied due to concerns that future application for human pain may be limited by donor availability. Despite immune privileges of the CNS, xenografts require at least short-term immunosuppression to obtain a viable graft. Cell encapsulation is one method of sustaining a xenograft (in rat and human hosts) while circumventing the need for immunosuppression.Clinical studies have been initiated for terminal cancer patients with promising results as assessed by markedly reduced narcotic intake, visual analog scale ratings, and increased CSF levels of catecholamines and met-enkephalin.

AB - The transplantation of cells that secrete neuroactive substances with analgesic properties into the CNS is a novel method that challenges current approaches in treating chronic pain. This review covers pre-clinical and clinical studies from both allogeneic and xenogeneic sources. One cell source that has been utilized successfully is the adrenal chromaffin cell, since such cells constitutively release catecholamines, opioid peptides, and neurotrophic factors; release can be augmented with nicotine. Other graft sources include AtT-20 and B-16 cell lines which release enkephalins and catecholamines, respectively. For grafting in rodents, adrenal medullary tissue pieces are transplanted to the subarachnoid space. Chromaffin cell transplants can decrease pain sensitivity in normal rats using standard acute pain tests (paw-pinch, hot-plate, and tail-flick). In addition, transplants can restore normal pain thresholds in rodent models of chronic pain (formalin, adjuvant-induced arthritis, and sciatic-nerve tie) which closely similate the pathologies of human chronic pairs conditions. Xenografts have been studied due to concerns that future application for human pain may be limited by donor availability. Despite immune privileges of the CNS, xenografts require at least short-term immunosuppression to obtain a viable graft. Cell encapsulation is one method of sustaining a xenograft (in rat and human hosts) while circumventing the need for immunosuppression.Clinical studies have been initiated for terminal cancer patients with promising results as assessed by markedly reduced narcotic intake, visual analog scale ratings, and increased CSF levels of catecholamines and met-enkephalin.

UR - http://www.scopus.com/inward/record.url?scp=0029126146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029126146&partnerID=8YFLogxK

U2 - 10.1016/0301-0082(95)00011-J

DO - 10.1016/0301-0082(95)00011-J

M3 - Article

C2 - 8532850

AN - SCOPUS:0029126146

VL - 46

SP - 507

EP - 529

JO - Progress in Neurobiology

JF - Progress in Neurobiology

SN - 0301-0082

IS - 5

ER -